Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

The Utility of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Assay in Detecting Abnormalities in Lipid Metabolism and Cardiovascular Risk in an HIV-Infected South African Cohort.

Mayne ES, Moabi H, Grobbee DE, Barth RE, Klipstein-Grobusch K, Stevens WS, Vos AG, Louw S.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619883944. doi: 10.1177/1076029619883944.

PMID:
31686546
2.

Addressing antiretroviral therapy-related diagnostic coverage gaps across South Africa using a programmatic approach.

Cassim N, Coetzee LM, Stevens WS, Glencross DK.

Afr J Lab Med. 2018 Nov 12;7(1):681. doi: 10.4102/ajlm.v7i1.681. eCollection 2018.

3.

Correction: Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa.

Fox MP, Bor J, Brennan AT, MacLeod WB, Maskew M, Stevens WS, Carmona S.

PLoS Med. 2018 Aug 10;15(8):e1002643. doi: 10.1371/journal.pmed.1002643. eCollection 2018 Aug.

4.

Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa.

Fox MP, Bor J, Brennan AT, MacLeod WB, Maskew M, Stevens WS, Carmona S.

PLoS Med. 2018 Jun 11;15(6):e1002589. doi: 10.1371/journal.pmed.1002589. eCollection 2018 Jun. Erratum in: PLoS Med. 2018 Aug 10;15(8):e1002643.

5.

Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care.

Stevens WS, Gous NM, MacLeod WB, Long LC, Variava E, Martinson NA, Sanne I, Osih R, Scott LE.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):65-73. doi: 10.1097/QAI.0000000000001456.

PMID:
28542080
6.

Choosing a new CD4 technology: Can statistical method comparison tools influence the decision?

Scott LE, Kestens L, Pattanapanyasat K, Sukapirom K, Stevens WS.

Cytometry B Clin Cytom. 2017 Nov;92(6):465-475. doi: 10.1002/cyto.b.21522. Epub 2017 May 24.

7.

Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control.

Stevens WS, Scott L, Noble L, Gous N, Dheda K.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TBTB2-0040-2016. Review.

PMID:
28155817
8.

Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.

Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Van Vuuren C, Macleod W, Sanne I, Stevens WS, Carmona SC.

J Infect Dis. 2016 Dec 15;214(12):1826-1830. Epub 2016 Oct 20.

PMID:
27923946
9.

Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.

Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, MacLeod W, Sanne I, Stevens WS.

PLoS One. 2016 Dec 1;11(12):e0166305. doi: 10.1371/journal.pone.0166305. eCollection 2016.

10.

Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.

Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TFR, Hamers RL.

Lancet Infect Dis. 2016 Nov;16(11):e267-e275. doi: 10.1016/S1473-3099(16)30118-9. Epub 2016 Aug 25.

PMID:
27569762
11.

HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.

Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Variava E, MacLeod W, Sanne I, Stevens WS, Carmona S.

J Antimicrob Chemother. 2017 Jan;72(1):210-219. Epub 2016 Sep 22.

PMID:
27659733
12.

Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset.

Azzoni L, Barbour R, Papasavvas E, Glencross DK, Stevens WS, Cotton MF, Violari A, Montaner LJ.

PLoS One. 2015 Dec 15;10(12):e0145320. doi: 10.1371/journal.pone.0145320. eCollection 2015.

13.

Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa.

Gous NM, Scott LE, Potgieter J, Ntabeni L, Sanne I, Stevens WS.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):e34-43. doi: 10.1097/QAI.0000000000000872.

PMID:
26484742
14.

An investigation of fingerstick blood collection for point-of-care HIV-1 viral load monitoring in South Africa.

Maiers TJ, Gous N, Nduna M, McFall SM, Kelso DM, Fisher MJ, Palamountain KM, Scott LE, Stevens WS.

S Afr Med J. 2015 Mar;105(3):228-31.

PMID:
26294832
15.

Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.

Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, Erasmus LK, Ndjeka NO, Mvusi L, Vassall A, Sinanovic E, Cox HS, Dye C, Grant AD, Fielding KL.

Lancet Glob Health. 2015 Aug;3(8):e450-e457. doi: 10.1016/S2214-109X(15)00100-X.

16.

High incidence of latent tuberculous infection among South African health workers: an urgent call for action.

McCarthy KM, Scott LE, Gous N, Tellie M, Venter WD, Stevens WS, Van Rie A.

Int J Tuberc Lung Dis. 2015 Jun;19(6):647-53. doi: 10.5588/ijtld.14.0759.

PMID:
25946353
17.

CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy.

Peeling RW, Sollis KA, Glover S, Crowe SM, Landay AL, Cheng B, Barnett D, Denny TN, Spira TJ, Stevens WS, Crowley S, Essajee S, Vitoria M, Ford N.

PLoS One. 2015 Mar 19;10(3):e0115019. doi: 10.1371/journal.pone.0115019. eCollection 2015. Review.

18.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

Kumarasamy N, Aga E, Ribaudo HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Bartlett JA.

Clin Infect Dis. 2015 May 15;60(10):1552-8. doi: 10.1093/cid/civ109. Epub 2015 Feb 18.

19.

High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos MA, Carmona SC, Stevens WS.

PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.

20.

Time to reduce CD4+ monitoring for the management of antiretroviral therapy in HIV-infected individuals.

Stevens WS, Ford N.

S Afr Med J. 2014 Jun 20;104(8):559-60. doi: 10.7196/samj.8299. No abstract available.

PMID:
25213847
21.

The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.

Sarzotti-Kelsoe M, Needham LK, Rountree W, Bainbridge J, Gray CM, Fiscus SA, Ferrari G, Stevens WS, Stager SL, Binz W, Louzao R, Long KO, Mokgotho P, Moodley N, Mackay M, Kerkau M, McMillion T, Kirchherr J, Soderberg KA, Haynes BF, Denny TN.

J Immunol Methods. 2014 Jul;409:21-30. doi: 10.1016/j.jim.2014.05.013. Epub 2014 Jun 5.

22.

Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa.

Scott LE, Beylis N, Nicol M, Nkuna G, Molapo S, Berrie L, Duse A, Stevens WS.

J Clin Microbiol. 2014 Jun;52(6):1818-23. doi: 10.1128/JCM.03553-13. Epub 2014 Mar 12.

23.

Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa.

Ketseoglou I, Lukhwareni A, Steegen K, Carmona S, Stevens WS, Papathanasopoulos MA.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):289-93. doi: 10.1089/AID.2013.0267. Epub 2013 Dec 13.

24.

Prevalence, risk factors and risk perception of tuberculosis infection among medical students and healthcare workers in Johannesburg, South Africa.

van Rie A, McCarthy K, Scott L, Dow A, Venter WD, Stevens WS.

S Afr Med J. 2013 Sep 30;103(11):853-7. doi: 10.7196/samj.7092.

PMID:
24148172
25.

HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.

Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.

PMID:
23892239
26.

Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa.

Schnippel K, Meyer-Rath G, Long L, Stevens WS, Sanne I, Rosen S.

S Afr Med J. 2013 Jan 14;103(2):101-6. doi: 10.7196/samj.6182.

PMID:
23374320
27.

Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations.

Bergeron M, Daneau G, Ding T, Sitoe NE, Westerman LE, Stokx J, Jani IV, Coetzee LM, Scott L, De Weggheleire A, Boel L, Stevens WS, Glencross DK, Peter TF.

PLoS One. 2012;7(8):e41166. doi: 10.1371/journal.pone.0041166. Epub 2012 Aug 9. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/71a6d947-c034-4749-a33d-971284ea3408.

28.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team.

N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524. Epub 2012 Jul 11.

29.

Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.

Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM; ART-A Consortium.

AIDS. 2012 Aug 24;26(13):1663-72.

PMID:
22695297
30.

Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.

Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, Stevens WS, Rosen S.

Trop Med Int Health. 2012 Sep;17(9):1142-51. doi: 10.1111/j.1365-3156.2012.03028.x. Epub 2012 Jun 12.

31.

Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries.

Sigaloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ive P, Botes ME, Kityo C, Mandaliya K, Wellington M, Osibogun A, Geskus RB, Stevens WS, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance.

Clin Infect Dis. 2012 May;54 Suppl 4:S294-9. doi: 10.1093/cid/cir1015.

PMID:
22544190
32.

Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network.

Hamers RL, Straatsma E, Kityo C, Wallis CL, Stevens WS, Sigaloff KC, Siwale M, Conradie F, Botes ME, Mandaliya K, Wellington M, Osibogun A, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance.

Clin Infect Dis. 2012 May;54 Suppl 4:S261-5. doi: 10.1093/cid/cir995.

PMID:
22544185
33.

Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW; CIPRA-SA Project 1 Study Team.

Clin Infect Dis. 2012 Sep;55(5):737-45. Epub 2012 May 22.

34.

HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

Bronze M, Steegen K, Wallis CL, De Wolf H, Papathanasopoulos MA, Van Houtte M, Stevens WS, de Wit TR, Stuyver LJ; ART-A Consortium.

PLoS One. 2012;7(4):e34708. doi: 10.1371/journal.pone.0034708. Epub 2012 Apr 9.

35.

Clinical research and development of tuberculosis diagnostics: moving from silos to synergy.

Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S.

J Infect Dis. 2012 May 15;205 Suppl 2:S159-68. doi: 10.1093/infdis/jis194. Epub 2012 Apr 3. Review.

36.

Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER).

Clin Infect Dis. 2012 Jun;54(11):1660-9. doi: 10.1093/cid/cis254. Epub 2012 Apr 3.

PMID:
22474222
37.

Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Infect Dis. 2012 Jun;205(11):1739-44. doi: 10.1093/infdis/jis261. Epub 2012 Mar 23.

PMID:
22448003
38.

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.

Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N.

AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066.

39.

Perspectives on introduction and implementation of new point-of-care diagnostic tests.

Palamountain KM, Baker J, Cowan EP, Essajee S, Mazzola LT, Metzler M, Schito M, Stevens WS, Young GJ, Domingo GJ.

J Infect Dis. 2012 May 15;205 Suppl 2:S181-90. doi: 10.1093/infdis/jis203. Epub 2012 Mar 7.

40.

Mediastinal goiter presenting with ventricular tachycardia.

Gilbert KC, Dhiwakar M, Stevens WS, Robbins KT.

Head Neck. 2013 Jun;35(6):E194-6. doi: 10.1002/hed.22956. Epub 2012 Feb 2.

PMID:
22302698
41.

Performance evaluation of the Pima™ point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa.

Glencross DK, Coetzee LM, Faal M, Masango M, Stevens WS, Venter WF, Osih R.

J Int AIDS Soc. 2012 Jan 30;15(1):3. doi: 10.1186/1758-2652-15-3.

42.

Phased implementation of screening for cryptococcal disease in South Africa.

Govender NP, Chetty V, Roy M, Chiller T, Oladoyinbo S, Maotoe T, Stevens WS, Pinini Z, Spencer D, Venter WD, Jassat W, Cameron D, Meintjes G, Mbengashe T, Pillay Y.

S Afr Med J. 2012 Oct 8;102(12):914-7. doi: 10.7196/samj.6228. No abstract available.

PMID:
23498036
43.

Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study.

Jaspan HB, Myer L, Madhi SA, Violari A, Gibb DM, Stevens WS, Dobbels E, Cotton MF.

BMC Pediatr. 2011 Nov 21;11:104. doi: 10.1186/1471-2431-11-104.

44.

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.

Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Wit FW, van Vugt M, Stevens WS, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER) Investigators.

Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27.

PMID:
22036233
45.

Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.

Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, Stevens WS.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):171-5. doi: 10.1089/aid.2011.0136. Epub 2011 Aug 5.

PMID:
21819219
46.

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.

PMID:
21802367
47.

Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34.

PMID:
21694603
48.

The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.

Rosen S, Long L, Sanne I, Stevens WS, Fox MP.

J Int AIDS Soc. 2011 May 15;14:24. doi: 10.1186/1758-2652-14-24.

49.

Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.

Papasavvas E, Azzoni L, Foulkes A, Violari A, Cotton MF, Pistilli M, Reynolds G, Yin X, Glencross DK, Stevens WS, McIntyre JA, Montaner LJ.

Pediatr Infect Dis J. 2011 Oct;30(10):877-82. doi: 10.1097/INF.0b013e31821d141e.

50.

Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective.

Wiggill TM, Mantina H, Willem P, Perner Y, Stevens WS.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):460-6. doi: 10.1097/QAI.0b013e31820bb06a.

PMID:
21239997

Supplemental Content

Loading ...
Support Center